Alejandro Fuentes, MD
Family Medicine · Weslaco, TXNPI 1619940475
Payments from drug & device makers
Across 80 payments — averaging $26.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$386
- AstraZeneca$313
- Novo Nordisk$290
- Sanofi-aventis U.S. LLC$187
- Romark Laboratories, LC$182
- Vifor Pharma, Inc.$125
- plus $606 from 15 others
What the payments were for
- Speaking & faculty fees$34817%
- Food & beverage$1,72583%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 4 | $386 |
| AstraZeneca | 8 | $313 |
| Novo Nordisk | 14 | $290 |
| Sanofi-aventis U.S. LLC | 7 | $187 |
| Romark Laboratories, LC | 10 | $182 |
| Vifor Pharma, Inc. | 1 | $125 |
| Optinose US, Inc. | 2 | $125 |
| AbbVie(2 entities) | 7 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $64 |
| GSK | 4 | $51 |
| Amarin Pharma, Inc. | 3 | $45 |
| Lilly USA, LLC | 3 | $40 |
| Merck | 3 | $38 |
| Mannkind Corporation | 2 | $26 |
| Astellas Pharma US Inc | 1 | $17 |
| Novartis | 1 | $17 |
| Pfizer | 1 | $15 |
| Amgen | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,088 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 84 | $97,594 |
| EliquisApixaban | 72 | $78,331 |
| JardianceEmpagliflozin | 57 | $74,935 |
| OzempicSemaglutide | 52 | $73,449 |
| TrulicityDulaglutide | 46 | $73,028 |
| TradjentaLinagliptin | 81 | $62,724 |
| LinzessLinaclotide | 68 | $49,927 |
| XifaxanRifaximin | 11 | $33,638 |
| MounjaroTirzepatide | 26 | $31,394 |
| XareltoRivaroxaban | 29 | $25,312 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $25,086 |
| FarxigaDapagliflozin Propanediol | 19 | $25,035 |
| RybelsusSemaglutide | 19 | $24,198 |
| MyrbetriqMirabegron | 29 | $20,748 |
| VascepaIcosapent Ethyl | 23 | $11,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $38 | $122,679103 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $40 | $104,42272 claims |
| Novo NordiskOzempic, Rybelsus | $290 | $97,64771 claims |
| PfizerEliquis | $15 | $78,33172 claims |
| AbbVieLinzess | $117 | $49,92768 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $64 | $33,63811 claims |
| AstraZenecaFarxiga, Symbicort | $313 | $29,48137 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $20,74829 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $51 | $19,22438 claims |
| NovartisEntresto | $17 | $9,11212 claims |
| Sanofi-aventis U.S. LLCMultaq | $187 | $8,22711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Weslaco
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.